PrEP support via telehealth for people who inject drugs
Part of Infections clinical trials.
This trial tests whether telehealth support can help people who inject drugs start and stay on PrEP (HIV prevention medicine). You will join several sessions and follow-up visits to see if this approach works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have injected drugs at least once in the past month.
- In the last 6 months, you have had a reason to take PrEP (for example, shared needles or sex without condoms with someone at risk of HIV).
- You are already a client of the county health department’s syringe service program (SSP).
- You are willing to take part in multiple study sessions and follow-up appointments.
- You do not have HIV, and you are not already taking PrEP.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different ways to help people who inject drugs stay on PrEP, a daily pill that prevents HIV. It's for people who are HIV-negative and have recently injected drugs.
This study looks at using social connections to help people who inject drugs get HIV prevention and substance use support. The trial tests a program in Los Angeles that works with friends or peers to encourage PrEP (HIV prevention pills) and addiction treatment.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
This study tests whether pharmacies can safely provide HIV prevention medications (PrEP for prevention, PEP for emergency treatment) and HIV testing through phone or video visits. It aims to make these services easier to access without visiting a hospital or clinic.
This trial looks at how well a daily HIV-prevention pill (F/TAF) works in people who use drugs. The goal is to understand real-world effectiveness and help support people in staying HIV-negative.
Hear when a new HIV Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.